SCHEMBL4767157

SCHEMBL4767157

CN1CCN(Cc2cccc(-c3cc4c(Nc5ccc(F)c(Cl)c5)ncnc4[nH]3)c2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 2/20 0.52
EGFR P00533 15/20 0.51
ERBB2 P04626 6/20 0.48
ERBB4 Q15303 3/20 0.47
JAK3 P52333 1/20 0.47
STK10 O94804 1/20 0.47
MAP4K4 O95819 1/20 0.47
ABL1 P00519 1/20 0.47
YES1 P07947 1/20 0.47
RET P07949 1/20 0.47
PDGFRB P09619 1/20 0.47
BCR P11274 1/20 0.47
FLT1 P17948 1/20 0.47
ERBB3 P21860 1/20 0.47
WEE1 P30291 1/20 0.47
KDR P35968 1/20 0.47
ABL2 P42684 1/20 0.47
NEK3 P51956 1/20 0.47
LIMK1 P53667 1/20 0.47
LIMK2 P53671 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4765712 0.93 EGFR (0.55) AXLEGFRERBB2ERBB4STK10
SCHEMBL4764690 0.92 AXL (0.56) AXLEGFRERBB2ERBB4JAK3
SCHEMBL4765901 0.92 EGFR (0.54) EGFRERBB2ERBB4JAK3STK10
SCHEMBL4766665 0.91 EGFR (0.54) EGFRERBB2ERBB4JAK3STK10
SCHEMBL4766866 0.90 EGFR (0.55) AXLEGFRERBB2ERBB4JAK3
SCHEMBL4769248 0.88 EGFR (0.56) EGFRERBB2ERBB4JAK3KDR
SCHEMBL4766999 0.85 EGFR (0.62) AXLEGFRERBB2ERBB4STK10
SCHEMBL4772569 0.85 EGFR (0.50) EGFRERBB2PDGFRBKDREPHB4
SCHEMBL4718830 0.85 EGFR (0.51) EGFRERBB2PDGFRBKDREPHB4
SCHEMBL4771139 0.84 BRAF (0.45) EGFRERBB2ERBB4STK10MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1416935-B1 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2008-03-12 EP claimed
US-7244729-B2 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives NOVARTIS AG (CH) 2007-07-17 US claimed
US-20040248911-A1 7H-pyrrolo[2,3-d]pyrimidine derivatives BOLD GUIDO (CH) 2004-12-09 US claimed
US-20040242600-A1 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives NOVARTIS AG (CH) 2004-12-02 US claimed
EP-1416935-B1 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2008-03-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248911-A1 7H-pyrrolo[2,3-d]pyrimidine derivatives DPYD, DHPS, TYMP AXL 2837/4885EGFR 3391/4885ERBB2 2012/4885
US-20040242600-A1 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives DPYD, TYMP, TYMS AXL 2333/4885EGFR 2694/4885ERBB2 1341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.